ARTICLE | Product Development
The growing pool of gene editing delivery companies
As interest in systemic gene editing builds, so does the number of delivery-focused biotechs
February 27, 2021 1:37 AM UTC
Delivery technologies are likely to rise on the list of business development priorities for gene editing companies as they move into in vivo administration for systemic diseases, and a crop of companies is forming around that opportunity.
On Tuesday, base editing company Beam Therapeutics Inc. (NASDAQ:BEAM) announced the acquisition of Guide Therapeutics Inc. for $120 million up front in stock. The deal could be an early example of a trend in gene editing companies acquiring or in-licensing complementary delivery technologies...